149 related articles for article (PubMed ID: 23680211)
1. Effectiveness of topical maxacalcitol for acquired perforating disorder.
Yoshiya H; Okuyama R; Uhara H
J Am Acad Dermatol; 2013 Jun; 68(6):e181-2. PubMed ID: 23680211
[No Abstract] [Full Text] [Related]
2. Successful treatment of warts with a combination of maxacalcitol ointment and salicylic acid sticking plaster.
Inaba H; Suzuki T; Adachi A; Tomita Y
J Dermatol; 2006 May; 33(5):383-5. PubMed ID: 16700677
[No Abstract] [Full Text] [Related]
3. Treatment of genital lichen sclerosus with topical calcipotriol.
Gupta S; Saraswat A; Kumar B
Int J STD AIDS; 2005 Nov; 16(11):772-4. PubMed ID: 16303082
[No Abstract] [Full Text] [Related]
4. Successful treatment of acquired reactive perforating collagenosis with topical benzoyl peroxide: A possible therapeutic action underlying structural and metabolic turnover.
Miyanaga M; Oyama N; Sakai Y; Imamura Y; Hasegawa M
J Dermatol; 2020 Jan; 47(1):e12-e14. PubMed ID: 31599039
[No Abstract] [Full Text] [Related]
5. Effect of topical calcipotriol on inflammatory linear verrucous epidermal nevus.
Micali G; Nasca MR; Musumeci ML
Pediatr Dermatol; 1995 Dec; 12(4):386-7. PubMed ID: 8747593
[No Abstract] [Full Text] [Related]
6. Treatment of psoriasis vulgaris with narrow-band UVB and topical Maxacalcitol.
Takekoshi T; Asahina A; Komine M; Tamaki K
Acta Derm Venereol; 2006; 86(4):375-6. PubMed ID: 16874435
[No Abstract] [Full Text] [Related]
7. A case of generalized pustular psoriasis treated with topical tacrolimus.
Nagao K; Ishiko A; Yokoyama T; Tanikawa A; Amagai M
Arch Dermatol; 2003 Sep; 139(9):1219. PubMed ID: 12975175
[No Abstract] [Full Text] [Related]
8. Topical calcipotriol for treatment of inflammatory linear verrucous epidermal nevus.
Zvulunov A; Grunwald MH; Halvy S
Arch Dermatol; 1997 May; 133(5):567-8. PubMed ID: 9158408
[No Abstract] [Full Text] [Related]
9. Infantile acropustulosis treated successfully with topical maxacalcitol.
Kimura M; Higuchi T; Yoshida M
Acta Derm Venereol; 2011 May; 91(3):363-4. PubMed ID: 21336473
[No Abstract] [Full Text] [Related]
10. [How I treat...pityriasis rubra pilaris].
Fraiture AL; Braham C; Piérard-Franchimont C; Piérard GE
Rev Med Liege; 2002 Jun; 57(6):363-5. PubMed ID: 12180027
[TBL] [Abstract][Full Text] [Related]
11. The use of topical calcipotriene/calcipotriol in conditions other than plaque-type psoriasis.
Thiers BH
J Am Acad Dermatol; 1997 Sep; 37(3 Pt 2):S69-71. PubMed ID: 9344189
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of subcorneal pustular dermatosis with maxacalcitol.
Hoshina D; Tsujiwaki M; Furuya K
Clin Exp Dermatol; 2016 Jan; 41(1):102-3. PubMed ID: 25991581
[No Abstract] [Full Text] [Related]
13. Successful treatment of refractory warts with topical vitamin D3 derivative (maxacalcitol, 1alpha, 25-dihydroxy-22-oxacalcitriol) in 17 patients.
Imagawa I; Suzuki H
J Dermatol; 2007 Apr; 34(4):264-6. PubMed ID: 17352726
[No Abstract] [Full Text] [Related]
14. Comparative efficacy of topical antipsoriatic treatments, systemic treatment and biologics: is severity assessment beyond Psoriasis Area and Severity Index a necessity?
van de Kerkhof PC; Mrowietz U; Segaert S; Kragballe K
Br J Dermatol; 2007 Apr; 156(4):771-2. PubMed ID: 17263798
[No Abstract] [Full Text] [Related]
15. Calcipotriol in other dermatological disorders.
Br J Clin Pract Suppl; 1996 Feb; 83():29. PubMed ID: 8871487
[No Abstract] [Full Text] [Related]
16. A pediatric case of nephrogenic fibrosing dermopathy: improvement after combination therapy.
DiCarlo JB; Gupta EA; Solomon AR
J Am Acad Dermatol; 2006 May; 54(5):914-6. PubMed ID: 16635686
[No Abstract] [Full Text] [Related]
17. A case of mosaic-type bullous congenital ichthyosiform erythroderma successfully treated with topical maxacalcitol, a vitamin D3 analogue.
Umekoji A; Fukai K; Ishii M
Clin Exp Dermatol; 2008 Jul; 33(4):501-2. PubMed ID: 18498407
[No Abstract] [Full Text] [Related]
18. Confluent and reticulated papillomatosis: response to topical calcipotriol.
Kürkçüoğlu N; Celebi CR
Dermatology; 1995; 191(4):341-2. PubMed ID: 8573938
[No Abstract] [Full Text] [Related]
19. Sorilux (calcipotriene) foam 0.005%.
Abramovits W; Oquendo M; Scheinfeld N; Gupta AK
Skinmed; 2012; 10(5):301-4. PubMed ID: 23163073
[No Abstract] [Full Text] [Related]
20. In vivo assessment of the cutaneous bioavailability of topically applied maxacalcitol.
Ikeda Y; Hirata K; Kano S; Yanagihara H; Takahara J; Kondo K; Umemura K
Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):305-10. PubMed ID: 16082417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
